neonatology paediatrics
Rebound Hyperbilirubinemia Risk Score
Predicts risk of significant rebound hyperbilirubinaemia after discontinuation of phototherapy in neonates ≥35 weeks. Low-risk infants may not need post-phototherapy bilirubin checks. Identifies infants safe for early discharge after phototherapy.
References
- Chang PW, et al. A clinical prediction rule for rebound hyperbilirubinemia following inpatient phototherapy. Pediatrics. 2017;139(3):e20162896.
- Kaplan M, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Arch Dis Child. 2006;91(1):31–34.
- NICE CG98. Jaundice in newborn babies under 28 days. 2010 (updated 2016).
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Rozanolixizumab · Neonatal Fc receptor (FcRn) antagonist
- Efgartigimod alfa · Neonatal Fc receptor (FcRn) blocker
- Phenobarbital (Paediatric Epilepsy — Beyond Neonatal) · Barbiturate Anticonvulsant
- Gentamicin (Paediatric) · Aminoglycoside — Neonatal Sepsis / Gram-Negative Infections in Children
- Aciclovir (Paediatric) · Antiviral — HSV Encephalitis / Neonatal Herpes / VZV in Immunocompromised
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
